Core Insights - Dyne Therapeutics plans to announce topline clinical results from the Registrational Expansion Cohort of the Phase 1/2 DELIVER trial for zeleciment rostudirsen on December 8, 2025 [1] - A webcast will be hosted at 8:00 a.m. ET to discuss these results, with a press release to be issued beforehand [1][2] Company Overview - Dyne Therapeutics is focused on improving the functionality of individuals with genetically driven neuromuscular diseases [3] - The company is developing therapeutics targeting muscle and the central nervous system to address the root causes of diseases such as myotonic dystrophy type 1 and Duchenne muscular dystrophy, along with preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease [3]